BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062
Company: BioCity Biopharma
Indication: IgA nephropathy (IgAN), chronic kidney disease (CKD), diabetic kidney disease (DKD)
Drug: SC0062
Trial Phase: Phase 2
NCT ID: Not provided
Overview
BioCity Biopharma has announced the successful completion of patient enrollment for the IgA nephropathy (IgAN) cohort in their Phase II clinical trial assessing the safety and efficacy of SC0062. This oral drug is an endothelin A (ETA) receptor antagonist that could significantly impact the treatment landscape for patients with chronic kidney diseases including IgAN and DKD.
Enrollment for the DKD cohort is expected to conclude by the end of Q2 2024. The IgAN group's enrollment was completed within nine months, starting in June 2023, reflecting BioCity's efficiency in executing clinical trials.
As a leading entity in CKD research, BioCity intends to rapidly advance through the Phase II study and progress into Phase III trials in 2024. SC0062, a small molecule ETA receptor antagonist, has demonstrated promising safety, tolerability, and beneficial pharmacokinetics in prior phases.
The ongoing Phase II trial (CTR20230689), featuring over 40 active sites nationwide, is led by professor Jianghua Chen. While the IgAN patient group is fully enrolled, the DKD group is still enrolling participants.
BioCity Biopharma's commitment to innovation spans across various therapeutic areas, including cancer and autoimmune diseases, with a portfolio of over ten drug candidates such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.